Kailera Therapeutics Inc., a clinical-stage biotechnology company, will make its debut on the Nasdaq on April 17, 2026, under the ticker symbol "KLRA".
The company is offering 39.06 million shares of its common stock in the IPO, priced at $16 each. The offering is slated to close on April 20, 2026, with gross proceeds of $625.0 million.
In addition, Kailera has granted the underwriters a 30-day option to purchase up to an additional 5.86 million shares of common stock at the initial public offering price, less underwriting discounts and commissions.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.